Business
Dyadic Reports 2022 Year End Results and Recent Company Progress
Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19
About this update from Dyadic International, Inc.
[{"type":"text","content":"Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate which has completed dosing of all patients in both the low and high dose testing groupsOngoing research and license agreements with Janssen, Hengrui, NIIMBL and others for the C1-expressed therapeutic proteins for human health Expanded collaboration with Phibro/Abic and others to develop vaccines and treatments for companion and livestock animal diseasesInitiated multiple product candidates to support the newly launched Dapibus™ platform, a fungal-based microbial platform for use in non-pharmaceutical applications, such as food, nutrition, health, and wellnessNew license agreement with a Global Food Ingredient Company leveraging Dapibus™ to develop certain food proteinsFive manuscripts published in peer reviewed scientific journals demonstrating safety and persistence of C1-cell produced COVID-19 and influenza antigens New corporate website to reflect our scientific development expanded market focus in alternative proteins and revenue growth opportunities2022 revenue increased 21.9% YOYCash and investment grade securities of $12.7 million at year-end 2022Sale of equity interest in Alphazyme LLC; received approximately $1.27 million in January 2023Financial results and business update conference call scheduled for 5:00 pm ET today JUPITER, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced its financial results for year end 2022 and highlighted recent Company progress. “In 2022, we made significant advances in our technology and saw meaningful progress in each of our three core verticals,” said Mark Emalfarb, Dyadic's President and Chief Executive Officer, “Receiving regulatory approval for our First-In-Human Phase 1 trial for our proprietary DYAI-100 COVID-19 recombinant protein rec...